Role of the kallikrein-kinin system in the maturation of cardiovascular phenotype

被引:16
作者
Emanueli, C
Madeddu, P
机构
[1] Univ Sassari, Clin Med & Farmacol, I-07100 Sassari, Italy
[2] Natl Inst Biostruct & Biosyst, Nat Lab, Osilo, Italy
[3] Ist Dermopat Immacolata, Lab Vasc Pathol, Rome, Italy
关键词
bradykinin; kallikrein; kinin antagonist; renal function; blood pressure; phenotype; gene knockout; development;
D O I
10.1016/S0895-7061(99)00073-4
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Recent studies indicate that during early phases of life the kallikrein-kinin system (KKS) plays a role in kidney development, In the rat kidney, the spatial and temporal pattern of expression of the genes encoding for kallikrein or bradykinin (BK) B-2-receptors parallels postnatal nephrogenesis and blood now redistribution from the inner to the outer renal cortex. Animal models with genetic dysfunction of the renal KKS show alterations in the functional maturation of the kidney, and ultimately develop salt-sensitive hypertension. Kininogen-deficient Brown Norway Katholiek rats have undetectable urinary kinin levels and show an exaggerated blood pressure sensitivity to chronic excess of salt or mineralocorticoids. Another rat model with genetic reduction in urinary kallikrein excretion is characterized by an altered pressure-natriuresis relationship, with this defect being corrected by infusion of purified rat tissue kallikrein. Knockout mice lacking the BK B-2-receptor gene show elevated blood pressure and heart rate under basal conditions and enhanced blood pressure sensitivity to salt. In rats, prenatal blockade of the BK B-2-receptor by icatibant leads to a cardiovascular phenotype similar to that of animals with genetic defects of the KKS. Delayed renal maturation is observed when high salt intake is associated with icatibant. Collectively, these findings indicate a relevant role of the KKS in the physiologic maturation of renal and cardiovascular phenotypes. Genetic or environmental factors, able to potentiate the activity of the renal KKS, could protect against the development of arterial hypertension. (C) 1999 American Journal of Hypertension, Ltd.
引用
收藏
页码:988 / 999
页数:12
相关论文
共 83 条
[1]   Salt-sensitive hypertension in bradykinin B-2 receptor knockout mice [J].
Alfie, ME ;
Yang, XP ;
Hess, F ;
Carretero, OA .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 224 (03) :625-630
[2]   HORMONAL INDUCTION OF NA-K-ATPASE IN DEVELOPING PROXIMAL TUBULAR CELLS [J].
APERIA, A ;
LARSSON, L ;
ZETTERSTROM, R .
AMERICAN JOURNAL OF PHYSIOLOGY, 1981, 241 (04) :F356-F360
[3]   ENVIRONMENTAL FACTOR(S) DURING SUCKLING EXERT LONG-TERM EFFECTS UPON BLOOD-PRESSURE AND BODY-WEIGHT IN SPONTANEOUSLY HYPERTENSIVE AND NORMOTENSIVE RATS [J].
AZAR, S ;
KABAT, V ;
BINGHAM, C .
JOURNAL OF HYPERTENSION, 1991, 9 (04) :309-327
[4]   IMMUNOCYTOCHEMICAL LOCALIZATION OF RENIN AND KALLIKREIN IN THE RAT RENAL-CORTEX [J].
BARAJAS, L ;
POWERS, K ;
CARRETERO, O ;
SCICLI, AG ;
INAGAMI, T .
KIDNEY INTERNATIONAL, 1986, 29 (05) :965-970
[5]   A GENE FOR HIGH URINARY KALLIKREIN MAY PROTECT AGAINST HYPERTENSION IN UTAH KINDREDS [J].
BERRY, TD ;
HASSTEDT, SJ ;
HUNT, SC ;
WU, LL ;
SMITH, JB ;
ASH, KO ;
KUIDA, H ;
WILLIAMS, RR .
HYPERTENSION, 1989, 13 (01) :3-8
[6]  
BIANCHI G, 1994, TXB HYPERTENSION, P457
[7]   TARGETED DISRUPTION OF A B-2 BRADYKININ RECEPTOR GENE IN MICE ELIMINATES BRADYKININ ACTION IN SMOOTH-MUSCLE AND NEURONS [J].
BORKOWSKI, JA ;
RANSOM, RW ;
SEABROOK, GR ;
TRUMBAUER, M ;
CHEN, H ;
HILL, RG ;
STRADER, CD ;
HESS, JF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (23) :13706-13710
[8]   BRADYKININ PEPTIDES IN KIDNEY, BLOOD, AND OTHER TISSUES OF THE RAT [J].
CAMPBELL, DJ ;
KLADIS, A ;
DUNCAN, AM .
HYPERTENSION, 1993, 21 (02) :155-165
[9]   LOCAL HORMONAL FACTORS (INTRACRINE, AUTOCRINE, AND PARACRINE) IN HYPERTENSION [J].
CARRETERO, OA ;
SCICLI, AG .
HYPERTENSION, 1991, 18 (03) :58-69
[10]   RT-PCR microlocalization of bradykinin B2 receptor mRNA in microdissected rat nephron segments [J].
Castano, ME ;
Praddaude, F ;
Bompart, G ;
Girolami, JP ;
Bascands, JL .
IMMUNOPHARMACOLOGY, 1996, 33 (1-3) :171-173